其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Cerium(IV) Ammonium Nitrate CAS Registry Number: 16774-21-3; 10139-51-2 (nitric acid ammonium cerium salt) 硝酸铈铵

CAS Name: (OC-6-11)-Hexakis(nitrato-kO)-diammonium cerate(2-)
Additional Names: ammonium ceric nitrate; ammonium hexanitratocerate; ammonium nitratocerate
Percent Composition: Ce 25.56%, H 1...
Literature References: Versatile one-electron oxidizing agent. Prepn: G. F. Smith et al., Ind. Eng. Chem. Anal. Ed. 8, 449 (1936). Use as a primary standard in oxidimerty: G. F. Smith, W. H. Fly, Anal. Chem. 21, 1233 (1949). Improved prepn: G. F. Smith, Talanta 10, 709 (1963). Review of synthetic applications: J. R. Hwu, K.-Y. King, Curr. Sci. 81, 1043-1053 (2001); V. Nair et al., Acc. Chem. Res. 37, 21-30 (2004).

Iodosobenzene CAS Registry Number: 536-80-1 亚碘酰苯

CAS Name: Iodosylbenzene
Additional Names: PhIO
Percent Composition: C 32.75%, H 2.29%, I 57.68%, O 7.27%
Literature References: Versatile oxidizing agent. Prepn: C. Willgerodt, Ber. 26, 357 (1893). Synthesis: H. Saltzman, J. G. Sharefkin, Org. Synth. 5, 658 (1973). Mechanistic study: R. M. Moriarty et al., J. Am. Chem. Soc. 103, 686 (1981). Use as oxidant: S. Mukerjee et al., ibid. 119, 8097 (1997); G. Mielniczak, A. Lopusinski, Synlett 2001, 505; as mediator: P. Dauban et al., J. Am. Chem. Soc. 123, 7707 (2001); C.-C. Guo et al., Appl. Catal. A 230, 53 (2002). Brief review: A. Minatti, Synlett 2003, 140-141.

Dichloro(2-chlorovinyl)arsine CAS Registry Number: 541-25-3 路易士剂

CAS Name: (2-Chloroethenyl)arsonous dichloride
Additional Names: 2-chlorovinyldichloroarsine; chlorovinylarsine dichloride; Lewisite
Percent Composition: C 11.59%, H 0.97%, As 36.14%, Cl 51....
Literature References: Vesicant used as chemical weapon. Prepn: S. J. Green, T. S. Price, J. Chem. Soc. 119, 448 (1921); W. L. Lewis, G. A. Perkins, Ind. Eng. Chem. 15, 290 (1923). Review of military experience: G. N. Jarman in Adv. Chem. Ser. 23, entitled "Metal-Organic Compounds," M. Sittig, Ed. (ACS, Washington DC, 1959) pp 328-337. Determn of degradation products in soil: B. A. Tomkins et al., J. Chromatogr. A 909, 13 (2001); in urine: J. V. Wooten et al., J. Chromatogr. B 772, 147 (2002). Review of chemistry, toxicology and biological effects: M. Goldman, J. C. Dacre, Rev. Environ. Contam. Toxicol. 110, 75-115 (1989).

Benfotiamine CAS Registry Number: 22457-89-2 苯磷硫胺

CAS Name: Benzenecarbothioic acid S-[2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]-1-[2-(phosphonooxy)ethyl]-1-propenyl] ester
Additional Names: thiobenzoic acid S-ester with N-[(4-am...
Literature References: Vitamin B1 source. Prepn: A. Ito et al., DE 1130811 (1962), C.A. 57, 13764h (1962). Exists as 3 temperature dependent crystalline forms, a, g, d: A. Ito et al., Takamine Kenkyusho Nempo 14, 64 (1962); C.A. 59, 3920a (1963). Pharmacokinetics: H. Nogami et al., Chem. Pharm. Bull. 18, 1937 (1970). Clinical bioequivalence to thiamine: R. Bitsch et al., Ann. Nutr. Metab. 35, 292 (1991).

Calcipotriene CAS Registry Number: 112965-21-6 卡泊三醇

CAS Name: (1a,3b,5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol
Additional Names: (1S,1'E,3R,5Z,7E,20R)-9,10-seco-20-(3'-cyclopropyl-3'-hydroxyprop-1'-enyl)-1,...
Literature References: Vitamin D3 analog with low calcemic activity. Prepn: M. J. Calverley, E. T. Binderup, WO 8700834; eidem, US 4866048 (1987, 1989 both to Leo Pharm.); M. J. Calverley, Tetrahedron 43, 4609 (1987). Pharmacology: L. Binderup, E. Bramm, Biochem. Pharmacol. 37, 889 (1988); P. J. Marie et al., Bone 11, 171 (1990). Receptor binding: T. Valaja et al., Biochem. Pharmacol. 40, 1827 (1990). Review of clinical trials in psoriasis: D. M. Ashcroft et al., Br. Med. J. 320, 963-967 (2000).

Acenocoumarol CAS Registry Number: 152-72-7 醋硝香豆素

CAS Name: 4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-1-benzopyran-2-one
Additional Names: 3-(a-acetonyl-p-nitrobenzyl)-4-hydroxycoumarin; 3-(a-p-nitrophenyl-b-acetylethyl)-4-hydroxycoumarin;...
Literature References: Vitamin K antagonist; structurally similar to warfarin, q.v. Prepn: W. Stoll, F. Litvan, US 2648682 (1953 to Geigy); I. C. Ivanov et al., Arch. Pharm. 323, 521 (1990). Resolution and abs config of enantiomers: C. R. Wheeler, W. F. Trager, J. Med. Chem. 22, 1122 (1979). Pharmacology and toxicity: M. Leroux, B. Jamain, Therapie 11, 85 (1956). GC-MS determn in plasma: F. Pommier et al., J. Chromatogr. B 654, 35 (1994). Clinical trial: D. P. M. Brandjes et al., N. Engl. J. Med. 327, 1485 (1992).

Safinamide CAS Registry Number: 133865-89-1 沙芬酰胺

CAS Name: (2S)-2-[[[4-[(3-Fluorophenyl)methoxy]phenyl]methyl]amino]propanamide
Additional Names: (S)-(+)-2-[[4-(3-fluorobenzoxy)benzyl]amino]propanamidePercent Composition: C 67.53%, H 6.33%, F...
Literature References: Voltage-dependent sodium and calcium channel blocker; selective and reversible inhibitor of monoamine oxidase B (MAO-B). Prepn: P. Dostert et al., EP 400495; eidem, US 5236957 (1990, 1993 both to Farmitalia); and anticonvulsant activity: P. Pevarello et al., J. Med. Chem. 41, 579 (1998). Mechanism of action study: P. Salvati et al., J. Pharmacol. Exp. Ther. 288, 1151 (1999). Review of early clinical development: P. L. Chazot, Curr. Opin. Invest. Drugs 2, 809-813 (2001). Clinical pharmacokinetics and pharmacodynamics: A. Marzo et al., Pharmacol. Res. 50, 77 (2004). Clinical evaluation in Parkinson's disease: F. Stocchi et al., Neurology 63, 746 (2004).

Lysine Acetylsalicylate CAS Registry Number: 62952-06-1 赖氨匹林

CAS Name: DL-Lysine mono[2-(acetyloxy)benzoate]
Additional Names: lysine monosalicylate acetate; aspirin lysine salt; LAS
Trademarks: Aspidol (Piam); Aspisol (Bayer); Delgesic (Karlspharma);...
Literature References: Water soluble, injectable aspirin derivative. Prepn: FR 1295304 (1962 to Equilibre Biologique), C.A. 58, 1536f (1963). Prepn of D,L isomers and racemate: FR 2115060 (1972 to Metabio), C.A. 78, 75877k (1972). Comparison with aspirin: S. Rampon et al., Rhumatologie 24, 141 (1972). Pharmacokinetics: H. von Ross et al., Klin. Wochenschr. 56, 1119 (1978); F. Gentit, Gaz. Med. Fr. 86, 4539 (1979). Veterinary use as analgesic: P. Richez et al., J. Vet. Pharmacol. Ther. 2, 231 (1979); eidem, ibid. 3, 121 (1980). Analgesic activity in post-operative pain: K. Korttila et al., Br. J. Anaesth. 52, 613 (1980); in articular pain: C. Diaz et al., Clin. Ther. 4, 121 (1981). Use in treatment of premature labor: F. Wolff et al., Arch. Gynecol. 233, 15 (1982). Comparison with aspirin in production of gastromucosal damage: J.-F. Bretagne et al., Gastroenterol. Clin. Biol. 8, 28 (1984).

Androstenedione CAS Registry Number: 63-05-8 雄烯二酮

CAS Name: Androst-4-ene-3,17-dione
Additional Names: D4-androstenedione; D4-etiocholendione-3,17
Percent Composition: C 79.68%, H 9.15%, O 11.17%
Literature References: Weak androgen produced by the adrenal gland; converted in peripheral tissues to testosterone or estrone, q.q.v. Prepn: L. Ruzicka, A. Wettstein, Helv. Chim. Acta 18, 986 (1935); E. S. Wallis, E. Fernholz, J. Am. Chem. Soc. 57, 1511 (1935); and physiological activity: A. Butenandt, H. Kudszus, Z. Physiol. Chem. 237, 75 (1935). Isoln from adrenal cortex: J. von Euw, T. Reichstein, Helv. Chim. Acta 24, 879 (1941). Physiology: V. H. T. James, A. B. Goodall in Proc. 9th Congr. Hung. Soc. Endocrinol. Metab., F. A. Laszlo, Ed. (Akad. Kiado, Budapest, 1979) pp 235-241. HPLC determn in plasma or serum: V. R. Walker et al., Anal. Biochem. 234, 194 (1996). Discussion of use as dietary supplement: L. Schnirring, Physician Sportsmed. 26, 15-18 (1998). Clinical effect of oral supplement on blood chemistry: D. S. King et al., J. Am. Med. Assoc. 281, 2020 (1999).

Trifluoroethanol CAS Registry Number: 75-89-8 三氟乙醇

CAS Name: 2,2,2-Trifluoroethanol
Additional Names: TFE; 2,2,2-trifluoroethyl alcohol
Percent Composition: C 24.01%, H 3.02%, F 56.97%, O 15.99%
Literature References: Weakly acidic alcohol. Prepn: F. Swarts, Bull. Soc. Chim. Belg. 43, 471 (1934). Structural study: L. A. Curtiss et al., J. Am. Chem. Soc. 100, 79 (1978). Interaction with peptides and proteins: R. Rajan, P. Balaram, Int. J. Pept. Protein Res. 48, 328 (1996). Review of production and applications: S. Arai, Spec. Chem. 18, 294-297 (1998); of effects on peptide and protein structures: M. Buck, Q. Rev. Biophys. 31, 297-355 (1998).